https://www.fiercebiotech.com/biotech/transgene-announces-termination-by-roche-of-license-agreement-on-tg4001-rg3484-for
Transgene Announces the Termination by Roche of the License Agreement on TG4001/RG3484 for the Treatment of Diseases Caused by the HumanPapilloma Virus ("HPV")...
license agreementtransgeneannouncesterminationroche
https://www.livemint.com/transgene-biotek/profit-loss-annual/companyid-s0000547
Transgene Biotek Profit & Loss: Access Transgene Biotek comprehensive profit & loss Annual account statement. Stay informed on Transgene Biotek profit and loss...
transgenebiotekprofitlosscheck
https://vaccinenation.org/therapeutic/transgene-shares-disappointing-tg4001-study-update/
Oct 14, 2024 - Transgene announced in October 2024 that the primary objective of its randomised Phase II study of TG4001 has not been met. The study was evaluating
transgenesharesstudyupdate